the company's ceo neil kumar is standing by with angelica. >> hey, kelly, that's right. e with neil. thank you for joining us. appreciate it. you just got this drug approved for attr carbon dioxide. talk about the opportunity and how that launch is going. >> sure. thanks it affects some 300,000 americans, one of the most common causes of cardiovascular disease, which is the leading cause of death in the united states. and it uniformly arises if the destabilization of a protein and all we are doing is gluing that protein back together. the opportunity here is to really stave off death and cardiovascular hospitalization. that's what our product does. >> you are competing with pfizer. so how do you sew that competitive landscape looking. >> pfizer has done a wonderful job the last five years. what they have is sort of a semi potent glue, if you will, gluing that protein back together. we have a superglue, if you will. the only compound with near complete stabilization on the label. the impact of the druk as early as three months, never seen that before in this space, and 42%